Waters and BD will merge biosciences and diagnostics in a $17.5B deal via Reverse Morris Trust, creating a life sciences innovation leader.

BDX's overall topline in the second quarter of fiscal 2025 continues to benefit from strength in its Medical segment and geographic performances.

Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.9% year on year to $5.51 billion. The company’s outlook ...

BD Reports Third Quarter Fiscal 2025 Financial Results BD Reports Third Quarter Fiscal 2025 Financial Results PR Newswire FRANKLIN LAKES, N.J., Aug. 7, 2025 Revenue of $5.5 billion increased 10.4% ...

BD recently kicked off its inaugural BD Innovates webinar series with Spotlight on Pharmacy Automation. The session was moderated by Francesca DeMartino, senior vice president of investor ...